デキスフェンフルラミンで治療された患者におけるバルブロパシーの流行と決定因子
B K Shively1, C A Roldan, E A Gill
1Cardiology Divisions of Oregon Health Sciences University, Portland, OR, USA. shivelyb@ohsu.edu
Circulation
|November 26, 1999
まとめ
デックスフェンフルラミンの使用は,弁の再発,特に軽度の大動脈再発のリスクを高めます. この状態は,薬の投与を中止した後に改善されることがありますが,年齢と血圧も流行に影響します.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- クリニカル・メディシン 臨床医学
背景:
- デキスフェンフルラミンに関連したバルブ吐,しかし,有病率と重症度は不明である.
- デキスフェンフルラミンに関連した弁反発に寄与する要因はよくわかっていない.
研究 の 目的:
- デキスフェンフルラミン使用者におけるバルブ吐の罹患率と重症度を決定する.
- デキスフェンフルラミンに関連する弁反発に関連する要因を特定するために.
主な方法:
- 412人の被験者の心声検査 (172人のデクスフェンフルラミン患者,172人の対照群,68人の対照群).
- 3人のエコーカーディオグラファーによる独立した解釈.
- 年齢,血圧,治療中止後の時間など,再発症に関連する要因の分析.
主要な成果:
- デキスフェンフルラミン患者では,FDAグレードの嘔吐が著しく高頻度であった (7.6%対2.1%,P=0.01).
- 軽度の大動脈再発が主な原因であった (6.3%対1.6%,P<0.02).
- 高齢,高気圧,更年期間の短縮は,再発症と独立して関連していた.
結論:
- デックスフェンフルラミンの使用は,異常な弁の再発の有病率の増加と関連しています.
- 年齢と血圧は,嘔吐の頻度に影響を与える可能性があります.
- デックスフェンフルラミンに関連した弁の嘔吐は,中止後に回復する可能性があります.
関連する概念動画
Factors Influencing Drug Absorption: Disease States and Pharmacology
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Factors Affecting Protein-Drug Binding: Protein-Related Factors
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...


